Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
J Dent Res
; 86(10): 927-36, 2007 Oct.
Article
em En
| MEDLINE
| ID: mdl-17890668
ABSTRACT
Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Inibidores da Angiogênese
/
Neoplasias
/
Neovascularização Patológica
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Dent Res
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Austrália